GCC ATTR Amyloidosis Disease Landscape

Transthyretin amyloidosis (ATTR) causes progressive deposition of misfolded TTR protein as amyloid fibrils, predominantly affecting the heart (ATTR-CM) and, in hereditary forms, the peripheral nerves. The GCC cardiac amyloid landscape mirrors the pre-2019, pre-Tc-PYP Western world: most heart failure with preserved ejection fraction (HFpEF) and hypertrophic cardiomyopathy is attributed to the region's high background rates of hypertension and diabetes, without ATTR-specific workup. Tc-PYP scintigraphy is available at fewer than 8 GCC centres and TTR genetic testing at only 3–4 reference laboratories; the result is an estimated ATTR-CM burden of 15,000–25,000 patients against fewer than 1,000 diagnosed.

The GCC also carries its own hereditary ATTR (ATTRv) genetic signature. Alongside the globally recognised Val30Met founder mutation, Arabian Peninsula-specific variants have been documented: Ala97Ser in Saudi kindreds, Glu89Gln in UAE and Omani kindreds, and Thr60Ala in some Bahraini families, producing predominantly cardiac or mixed phenotypes across an estimated 500–1,000 GCC ATTRv patients. KFSH&RC maintains the only GCC-wide ATTRv genetic registry. Median diagnostic delay is 4–6 years from first heart-failure presentation, moving through a 5–7 step referral chain (general physician, cardiologist, echocardiography, cardiac MRI where available, ATTR consideration, Tc-PYP referral) with each step typically adding 6–18 months — and genetic testing for ATTRv is rarely ordered without an explicit cardiomyopathy-genetics referral.

This assessment is built from GCC cardiology society task-force estimates, the KFSH&RC ATTR genetic registry, and peer-reviewed regional case series, triangulated to distinguish estimated ATTR-CM burden (drawn from HFpEF/HCM misattribution literature) from confirmed diagnoses (drawn from Tc-PYP and genetic testing registries).

Formulary and access status is confirmed against NPHC and MOH evaluation records and SFDA registration rather than US/EU payer language, reflecting the GCC's specialist-cardiology-centred referral model and independent regulatory pathway.